Access & reimbursement

ESR1 Resistance Is Becoming a Treatment Pathway, Not a Footnote

Life insurers are moving from pricing metabolic risk to trying to reduce it

CLL Just Moved a Noncovalent BTK Inhibitor Into First Line

The Pandemic Deal Has A Hole.

Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.

Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.

Obesity Is Costing Europe Beyond the Clinic. A New Report Puts a Price on It

Cholangiocarcinoma Just Made FGFR2 Testing Harder to Ignore

Breast Cancer Radiation De-Escalation Has an Adherence Problem
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
